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Since the publication of the International Programme on
Chemical Safety (IPCS) Harmonized Scheme for Mutage-
nicity Testing, there have been a number of publications
addressing test strategies for mutagenicity. Safety assess-
ments of substances with regard to genotoxicity are
generally based on a combination of tests to assess effects
on three major end points of genetic damage associated
with human disease: gene mutation, clastogenicity and
aneuploidy. It is now clear from the results of international
collaborative studies and the large databases that are
currently available for the assays evaluated that no single
assay can detect all genotoxic substances. The World
Health Organization therefore decided to update the IPCS
Harmonized Scheme for Mutagenicity Testing as part of
the IPCS project on the Harmonization of Approaches to
the Assessment of Risk from Exposure to Chemicals. The
approach presented in this paper focuses on the identifi-
cation of mutagens and genotoxic carcinogens. Selection of
appropriate in vitro and in vivo tests as well as a strategy
for germ cell testing are described.
Introduction
Since the publication of the International Programme on
Chemical Safety (IPCS) Harmonized Scheme for Mutage-
nicity Testing (1), there have been a number of publications
addressing test strategies for mutagenicity (2–6) and reviews
thereof (7). In addition, analyses of test batteries and their
correlation with carcinogenicity (8–11) have indicated that
an optimal solution to this issue has not yet been found.
The 2005 International Workshop on Genotoxicity Testing
(IWGT) meeting in San Francisco, USA, discussed many
of these problems, and reports of this meeting (10,12) and
companion papers (13–16) have recently been published.
Safety assessments of substances with regard to genotoxicity
are generally based on a combination of tests to assess effects
on three major end points of genetic damage associated with
human disease: gene mutation (i.e. point mutations or
deletions/insertions that affect single or blocks of genes),
clastogenicity (i.e. structural chromosome changes) and
aneuploidy (i.e. numerical chromosome aberrations). It is
now clear from the results of international collaborative studies
and the large databases that are currently available for the
assays evaluated that no single assay can detect all genotoxic
substances. This is not surprising, as a wide variety of possible
genetic events can occur. For example, some mutagens
preferentially induce gene mutations by either base pair
substitutions or frameshift mechanisms, whereas others induce
chromosome mutations but show little or no evidence of
inducing gene mutations.
The World Health Organization (WHO) therefore decided to
update the IPCS Harmonized Scheme for Mutagenicity Testing
(1) as part of the IPCS project on the Harmonization of
Approaches to the Assessment of Risk from Exposure to
Chemicals. A public review draft paper was prepared by an
International Drafting Group Meeting of experts, held at the
Fraunhofer Institute for Toxicology and Experimental Medi-
cine in Hanover, Germany, on April 11–12, 2007, and revised,
following peer and public review, by an expert review meeting
hosted by the University of Bradford, Bradford, UK, on June
30 to July 1, 2008. The present paper is the product of the
expert review meeting.
Strategy for mutagenicity testing
The approach presented in this paper (see Figure 1) focuses on
the identification of mutagens and genotoxic carcinogens. The
term ‘mutation’ as understood in this paper (a glossary of
terms used in this paper is available on the IPCS website at
http://www.who.int/ipcs/publications/methods/harmonization/en
/index.html) refers to permanent changes in the structure and/
or amount of the genetic material of an organism that can lead
to heritable changes in its function, and it includes gene
mutations as well as structural and numerical chromosome
alterations. The group is aware of other mechanisms leading
to carcinogenicity and other heritable diseases, but their
identification requires additional types of mechanistic studies.
‘Genotoxicity’ refers to the capability of substances to damage
DNA and/or cellular components regulating the fidelity of
the genome—such as the spindle apparatus, topoisomerases,
DNA repair systems and DNA polymerases (4)—and includes
all adverse effects on genetic information. These potentially
harmful effects on genetic material may be mediated directly or
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indirectly and are not necessarily associated with mutagenicity.
Genotoxicity is therefore a broader term than ‘mutagenicity’,
which refers to the capacity to give rise to mutations.
Because of the wide range of genetic damage that can occur,
test batteries are designed to include complementary tests
evaluating different mechanisms of mutagenicity. At all stages
of the outlined testing strategy, a weight of evidence approach
and scientific judgement should be used. Multiple negative
results may not be sufficient to remove concern for mutagenicity
raised by a clear positive result in a single mutagenicity assay.
Most short-term tests in bacteria and mammalian cell
cultures have been designed primarily for hazard identification
and thus can represent only the starting point in the process
of risk assessment. Whether or not the observed effects are
relevant for humans under anticipated exposure conditions
depends on pharmacokinetic, pharmacodynamic and other
factors that require investigation in vivo.
Especially when choosing in vivo assays and when pro-
ceeding into germ cell mutagenicity studies (see Strategy for
germ cell testing), expert judgement is required to select the
Considerations prior to testing:
Strategy for mutagenicity testing
Chemical structure and class of the agent, chemical features such as solubility and stability
Expected metabolism, reactivity, biological activity, relationship to known genotoxins
Routes of exposure, bioavailability, and target tissue
In vitro testing (usually two or three from the following):
1) Bacterial test for gene mutation
2) Test for detection of chromosomal mutations, including indications for aneugenicity, e.g.
a) metaphase analysis
b) micronucleus test
3) Mammalian cell mutation assay (e.g. mouse lymphoma assay or HPRT assay)
Positive Negative
Contradictory or equivocal results
within or between tests
Further in vitro testing may be used
to clarify positive/negative results
Appropriate choice of
in vivo tests may be helped
by further analysis to determine
mode of action (MOA)
In vivo tests depending
on anticipated
level of human exposure
or special concerns
Presumed non-mutagenic
in vivo; no further tests
Cytogenetic (bone marrow) or gene mutation assay OR alternative test defined by MOA,
chemical class/reactivity, and considering bioavailability and metabolism, etc. (see Table III)
In vivo test
Positive NegativeEquivocal (after appropriate efforts
to improve sensitivity)
Equivocal (after appropriate efforts
to improve sensitivity)
Positive
Choose appropriate test(s), e.g comet assay, transgenic mutation assay,
based on end point, tissue, route of exposure, etc., as discussed in Table III
Additional test(s) in vivo
Additional testing or conclusion
based on weight of evidence
In vitro assay positive
In vivo somatic cell mutagen No evidence indicating in vivo mutagenicity
Germ cell testing – see Figure 2
+ve or
unresolved
–ve
Negative
Fig. 1. Strategy for mutagenicity testing.
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appropriate test systems and to avoid uninformative and thus
unnecessary animal experiments.
Development of a testing strategy
Before initiating mutagenicity testing on a particular substance
(or mixture of substances), the following aspects should be
considered, when available:
(i) Chemical structure and class of the substance (possible
structure–activity relationships) and physicochemical
properties, such as solubility and stability;
(ii) Expected pathways of metabolism, chemical and bi-
ological reactivity/activity and relationship to known
genotoxic substances and
(iii) Routes of exposure, bioavailability and target tissues for
genotoxicity.
Critical evaluation of available data prior to testing usually
provides important information for choosing the appropriate in
vitro assays, but even more so for the selection of appropriate
in vivo studies.
Distinction needs to be made between ‘mutagenicity tests’ in
the strict sense and ‘indicator tests’ that provide evidence of
interaction with DNA that may or may not lead to mutations
(e.g. DNA adducts, DNA strand breaks and sister chromatid
exchanges). Preference should be given to mutagenicity tests
whenever possible.
In vitro testing
Usually two or three different tests in bacteria and mammalian
cells are selected to cover the end points of gene mutations,
clastogenicity (structural chromosome aberrations) and aneu-
ploidy (numerical chromosome aberrations), taking into
account physicochemical properties of substances under
consideration.
In vitro tests. Screening should be based on a limited number
of tests that are well validated and informative. Genotoxicity
test batteries generally include the following:
(i) A test for gene mutation in bacteria (bacterial reverse
mutation assay): Organisation for Economic Co-operation
and Development (OECD) Test Guideline 471 recom-
mends the use of at least five strains of bacteria: (a)
Salmonella typhimurium TA1535, (b) S.typhimurium
TA1537 or TA97 or TA97a, (c) S.typhimurium TA98,
(d) S.typhimurium TA100 and (e) Escherichia coli WP2
or E.coli WP2uvrA or S.typhimurium TA102. The choice
of additional tests depends on the chemical structure and
class of the substance (see Development of a testing
strategy). Table I describes the most commonly used
bacterial mutagenicity tests.
(ii) In vitro mammalian assays: These assays should evaluate
the potential of a substance to induce point mutations,
clastogenicity and/or aneugenicity, by using either mam-
malian cell lines or primary human cell cultures such as
fibroblasts or lymphocytes (e.g. mouse lymphoma thymi-
dine kinase assay, hypoxanthine guanine phosphoribosyl-
transferase assay or cytogenetic evaluation of
chromosomal damage in mammalian cells via either the
in vitro chromosome aberration or the in vitro micronu-
cleus test) (see Table II).
Evaluation of in vitro testing results. In the evaluation, results
are classified into (i) positive, (ii) negative and (iii) contradic-
tory or equivocal:
(i) Positive: Substance is positive at one or more end points
of mutagenicity.
(ii) Negative: Substance is negative in all test systems
under appropriate in vitro test conditions; the substance
is not mutagenic (or genotoxic) in vitro and is anticipated
not to be mutagenic in vivo [for exceptions, see refs
(37,38)].
(iii) Contradictory or equivocal (e.g. borderline biological or
statistical significance): All other substances.
Follow-up to in vitro testing.
(i) Positive in vitro results
In vivo test; selection of an appropriate end point; if
necessary, further in vitro studies to optimize in vivo
testing (e.g. kinetochore staining as an addition in the
micronucleus assay of in vitro aneugens). Follow-up tests
in vitro may also provide additional mechanistic in-
formation to enable interpretation of a positive finding.
(ii) Negative in vitro results
In vivo testing is recommended in the case of ‘high’ or
‘moderate and sustained’ human exposure or for sub-
stances otherwise of high concern. In limited cases,
metabolic considerations may trigger in vivo testing (38).
(iii) Contradictory or equivocal in vitro results
Further in vitro testing to clarify positive or negative
results; depending on whether the situation is resolved by
further in vitro testing, proceed according to ‘positive’ or
‘negative’.
In vivo testing
In vivo tests. In vivo tests (see Tables III and IV) should be
chosen carefully to avoid an uninformative outcome and with
concern for animal welfare. Therefore, toxicokinetics, metab-
olism and chemical reactivity have to be considered carefully.
In vivo tests may also be used for evaluation of a dose–
response, species differences or mode of action determination.
The use of such tests needs to be considered on a case-by-case
basis for risk assessment purposes.
The choice of an in vivo follow-up test should be guided by
the spectrum of genotoxic events observed in the in vitro
studies as well as knowledge of the bioavailability, distribution,
metabolism and target organ specificity of the substance.
Typically, a bone marrow micronucleus or clastogenicity test is
conducted. However, if there are indications that point to
a more appropriate assay, then this assay should be conducted
instead (e.g. mutagenicity study with transgenic animals and/or
comet assay in potential target tissues).
Follow-up to in vivo testing.
(i) Positive in vivo results
Substance is considered an ‘in vivo somatic cell mutagen’.
Testing for germ cell mutagenicity (see Strategy for germ
cell testing) may be required.
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Table I. Common in vitro bacterial assays
Assay Strain End point Comments Published guidelines References
Salmonella typhimurium
reverse mutation assay
TA1535, TA1537
(or TA97 or TA97a),
TA98, TA100
Primarily detects
G/C base pair and
frameshift mutations
Contain specific mutations
in one of several genes
involved in histidine
biosynthesis that must
be reverted to function
normally. Testing with
and without appropriate
exogenous metabolic
activation system.
May not detect some
oxidizing mutagens and
cross-linking agents.
OECD Test Guideline
471 (replaces old
OECD Test
Guidelines 471 and 472)
(17–19)
S.typhimurium TA102 Primarily detects A/T
base pair damage
and small deletions
Detects oxidizing mutagens
and cross-linking agents
OECD Test
Guideline 471
(19,20)
Other S.typhimurium
mutants
YG1021, YG1026
(NR overexpression);
YG1024, YG1029
(NAT overexpression)
For detection of mutagenicity
of nitroaromatic and
aminoaromatic substances
that are bioactivated by
NR and NAT. More sensitive
than conventional strains.
Used for detecting
mutagenicity of toxic
pollutants in air, water
and food.
(21,22)
Escherichia coli reverse
mutation assay
WP2, WP2uvrA Primarily detects A/T
base pair damage
Detects oxidizing mutagens and
cross-linking agents
OECD Test
Guideline 471
(19)
A, adenine; C, cytosine; G, guanine; NAT, N-acetyltransferase; NR, nitroreductase; T, thymine.
Table II. Common in vitro mammalian assays
Assay Method/end point Main attributes Comments Published guidelines References
Mouse lymphoma TK
gene mutation assay
L5178Y mouse
lymphoma cell line;
using a selective
medium, mutant
frequencies
are determined
Detects not only point
mutations but also
various sizes of
chromosome deletions
and other effects that
can lead to loss of
heterozygosity (e.g.
mitotic recombination,
gene conversion and
translocations)
Use of positive controls and
colony sizing essential for
quality control. Evaluation
and interpretation changed
over the years. Recent protocol
updates recommendations.
Can be used as alternative to
metaphase analysis.
OECD Test Guideline
476; IWGT
guidelines
(3,23–26)
HPRT gene mutation assay Chinese hamster ovary,
AS52 or other suitable
cell line; using a
selective medium,
mutant frequencies are
determined
Detects not only point
mutations but also
small deletions; larger
deletions may be
detected in AS52 cells
Use of positive controls essential
for quality control
OECD Test
Guideline 476
(23,27)
Metaphase analysis
(in vitro mammalian
chromosome aberration
test)
A metaphase-arresting
substance (e.g. colchicine)
is applied; metaphase
cells are analysed
for the presence of
structural chromosome
aberrations
Detects clastogenicity;
some information on
aneugenicity can be
obtained with extended
culture times
A variety of cell lines, strains or
primary cell cultures, including
human cells, may be used (e.g.
Chinese hamster fibroblasts,
human or other mammalian
peripheral blood lymphocytes)
(28)
OECD Test
Guideline 473
(29–31)
Micronucleus test Detects micronuclei in the
cytoplasm of cultured
mammalian cells during
interphase
Detects both aneugenic
and clastogenic
substances; established
mammalian lines,
cultured human peripheral
blood lymphocytes or
Syrian hamster embryo
cells may be used
Several developments in updating
the protocol. Immunochemical
labelling of kinetochores or
hybridization with general or
chromosome-specific centromeric/
telomeric probes gives information
on the nature and mechanism of
formation of micronuclei induced
(whole chromosomes or fragments).
Draft OECD Test
Guideline 487
(13,32–36)
HPRT, hypoxanthine guanine phosphoribosyltransferase; TK, thymidine kinase.
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(ii) Negative in vivo results
Further in vivo testing is recommended in the case of
positive in vitro studies. Again, the second in vivo test is
chosen on a case-by-case basis, as stated above. If the test
is negative, it is concluded that there is no evidence for in
vivo mutagenicity.
(iii) Equivocal in vivo results
Equivocal results may be due to low statistical power,
which can be improved by increasing the number of
treated animals and/or scored cells.
If the situation is unresolved, a second in vivo test is
recommended, chosen on a case-by-case basis (ordinarily
on a different end point or in a different tissue, depending
on toxicokinetics, metabolism and mode of action);
proceed according to ‘positive’ or ‘negative’.
Strategy for germ cell testing
When information on the risk to the offspring of exposed
individuals is important, the following germ cell testing
strategy is recommended.
For substances that give positive results for mutagenic
effects in somatic cells in vivo, their potential to affect germ
cells should be considered. If there is toxicokinetic or
toxicodynamic evidence that germ cells are actually exposed
to the somatic mutagen or its bioactive metabolites, it is
reasonable to assume that the substance may also pose
a mutagenic hazard to germ cells and thus a risk to future
generations.
Where germ cell testing is indicated, judgement should be
used to select the most appropriate test strategy. There are
a number of tests available (summarized in Table IV), which
fall into two classes:
(i) Tests in germ cells per se (class 1)
(ii) Tests to detect effects in the offspring (or potential
offspring) of exposed animals (class 2)
Three tests that are available for such studies have
established OECD test guidelines:
(i) Clastogenicity in rodent spermatogonial cells (class 1):
OECD Test Guideline 483 (65)
Table III. Common in vivo genotoxicity assays
Assay End point Main attributes Comments Published guidelines References
Micronucleus test in
erythropoietic cells
Structural and numerical
chromosome alterations
Long history, regulatory
acceptance, high
relevance of end point
Has potential for
application to
other tissues
OECD Test
Guideline 474
(15,28), and
references
cited therein
Metaphase analysis
in vivo
Structural and numerical
chromosome aberrations
Long history, regulatory
acceptance, high
relevance of end point
Has potential for
application to
other tissues
OECD Test
Guideline 475
(39)
Transgenic animal
models
Gene mutation Can be applied to many
tissues. Gene specific.
No selective pressure
on mutations. Relevant
end point.
Need to optimize
protocols overall
and for each tissue.
lacI, lacZ, gpt
systems not sensitive
to the detection of
large deletions. Spi
system detects large
deletions.
IWGT, IPCS
guidance
(40–44)
Chemically modified
DNA
Covalent DNA adducts,
oxidative lesions
(e.g. 8-OH-dG)
Can be applied to many
tissues. Can be highly
sensitive (32P-postlabelling
or AMS) or chemically
specific (MS). Other
methods include
immunochemical techniques,
fluorescence, ECD
(for 8-OH-dG).
Indicator test detecting
premutagenic lesions.
Interpretation of results
can be complicated.
IWGT guidance (45)
DNA strand breakage
assays (e.g. comet assay)
DNA strand breaks,
alkali-labile lesions
Can be applied to many tissues.
Incorporation of enzymes
can improve specificity.
Cell division not required.
Indicator tests. Need to
optimize protocols for
different tissues. May
be unable to detect
mutagens that do not
induce strand breaks or
alkali-labile lesions, but
may detect repair-induced
breaks. Apoptosis/necrosis
need to be controlled.
IWGT guidance (14,46–49)
Liver UDS Thymidine incorporation
outside S phase
Long history of use; useful
for some classes of substances.
Indicator test detecting repair
activity. Uncertain acceptability
and questionable sensitivity.
Limited use in other tissues.
OECD Test
Guideline 486
(50,51)
8-OH-dG, 8-hydroxy-2#-deoxyguanosine; AMS, accelerator mass spectrometry; ECD, electrochemical detection; MS, mass spectrometry; UDS, unscheduled DNA
synthesis.
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(ii) The dominant lethal test (class 2): OECD Test Guideline
478 (66)
(iii) The mouse heritable translocation assay (class 2): OECD
Test Guideline 485 (67)
The above-mentioned class 2 tests usually require large
numbers of animals. Thus, in order to minimize the use of
animals in germ cell testing, it is advisable to start with tests that
detect effects in germ cells per se (class 1). Other methods
include (but are not limited to) gene mutation tests in transgenic
animals [see ref. (41) for IWGT guidance], gene mutations in the
more recent Expanded Simple Tandem Repeat (ESTR) assay,
chromosomal assays (including those using fluorescence in situ
hybridization), comet assay and DNA adduct analysis.
Following the use of such tests, if quantification of heritable
effects is required (class 2), an assay for ESTR mutations can
be performed with the offspring of a low number of exposed
animals. Tests used historically to investigate transmitted
effects (e.g. the heritable translocation test and the specific
locus test) can also be performed; however, they use large
numbers of animals.
Class 1 and class 2 germ cell assays are summarized in Table
IV. The strategy used in germ cell mutagenicity testing is
outlined in Figure 2.
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Table IV. Germ cell assays
Assay End point Main attributesa Comments Published
guidelines
References
Class 1: tests in
germ cells per se
Transgenic
animal models
Gene mutation Gene specific. No
selective pressure
on mutations.
Relevant end point.
See Table III See Table III See Table III
ESTR assay Non-coding tandem
repeat DNA mutation
Potentially relevant
end point. Detects
heritable mutations
at ambient exposure
levels. Uses relatively
few animals. Can be
conducted in humans.
Some tandem repeat
mutations also occur
in, or near, coding genes.
Although there are parallels
with mutations in coding
genes, the human health
outcomes require further study.
(52–55)
Mammalian
spermatogonial
chromosome
aberration test
Structural chromosome
aberrations
Relevant end point OECD Test
Guideline 483
(56)
FISH assays Structural chromosome
aberrations; sperm
aneuploidy
Relevant end points.
Can be conducted
in humans.
See Table III See Table III (57,58)
Comet assay DNA strand breaks or
alkali-labile sites
See Table III. Can be
conducted in humans.
See Table III See Table III (59)
Chemically
modified DNA
DNA adducts See Table III. Can be
conducted in humans.
See Table III See Table III (60)
Class 2: tests to detect
effects in the offspring
(or potential offspring)
ESTR assay As above for
class 1 tests
As above for
class 1 tests
As above for class 1 tests As above
for class
1 tests
Dominant lethal test Reduction in viable
embryos attributed
to chromosome or
gene mutations
Relevant end point.
Provides data for
quantification of
pregnancy loss.
OECD Test
Guideline 478
(61)
Mouse visible specific
locus test
Gene mutation Provides data for quantification
of inherited mutation
frequency. Relevant end point.
Uses large number
of animals
EPA OPPTS
870.5200
(62)
Mouse biochemical
specific locus test
Gene mutation Provides data for quantification
of inherited mutation
frequency. Relevant end point.
Uses large number
of animals
EPA OPPTS
870.5195
(63)
Mouse heritable
translocation assay
Structural chromosome
aberrations
Provides data for quantification
of inherited mutation
frequency. Relevant end point.
Uses large number
of animals
OECD Test
Guideline 485
(64)
EPA OPPTS, United States Environmental Protection Agency, Office of Prevention, Pesticides and Toxic Substances; ESTR, Expanded Simple Tandem Repeat;
FISH, fluorescence in situ hybridization.
a‘Relevant end point’ means relevant to the estimation of human heritable health risk.
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In vivo somatic cell mutagen– from Figure 1
Strategy for germ cell mutagenicity testing
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Evaluate toxicokinetic/toxicodynamic evidence that germ cells are exposed to test substance and that the substance 
 may pose mutagenic hazard to germ cells and risk to future generations (where applicable) 
Positive Negative 
Evidence of no exposure Evidence of exposure, or no exposure data 
In cases where no additional testing 
for characterization of risk is required, 
no further testing 
If germ cell testing undertaken, 
judgement used to select most 
appropriate test strategy 
Test(s) in gonadal cells per se from the following (see Table IV):
1) clastogenicity in rodent spermatogonial cells; 
2) gene mutation in transgenic animals; 
3) Expanded Simple Tandem Repeat (ESTR) mutation;
4) chromosomal analysis using fluorescence in situ hybridization (FISH);
5) comet assay; 
6) DNA adduct analysis 
Presumed not a
germ cell mutagen 
Established or presumed
germ cell mutagen
If quantification of heritable mutations
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genetic risk to offspring 
Fig. 2. Strategy in germ cell mutagenicity testing.
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